Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 27;21(1):1354.
doi: 10.1186/s12885-021-09097-5.

Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma

Ross S Greenberg  1 , Jake A Ruddy  1 , Brian J Boyarsky  1 , William A Werbel  2 , Jacqueline M Garonzik-Wang  1 , Dorry L Segev  3   4 , Philip H Imus  5
Affiliations

Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma

Ross S Greenberg et al. BMC Cancer. .

Abstract

Background: Patients with multiple myeloma (MM) were excluded from the original SARS-CoV-2 mRNA vaccine trials, which may influence vaccine hesitancy in this population. We prospectively characterized the safety and immunogenicity of two-dose SARS-CoV-2 mRNA vaccination in 44 patients with MM, who underwent vaccination from 12/17/2020 to 3/18/2021.

Results: Rates adverse reactions were low and consistent with those documented in vaccine trials. Among those on MM therapy, 93% developed detectable anti-receptor binding domain (RBD) antibodies after dose 2, while 94% of patients not on MM therapy seroconverted.

Conclusions: Two-dose SARS-CoV-2 mRNA vaccination is mildly reactogenic and leads to high rates of seroconversion in patients with MM. These findings can provide reassurance to MM patients who are hesitant to receive SARS-CoV-2 mRNA vaccines.

Keywords: Antibody; COVID-19; Multiple myeloma; SARS-CoV-2; mRNA vaccination.

PubMed Disclaimer

Conflict of interest statement

D.L.S. has the following financial disclosures: consulting and speaking honoraria from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallincrodt, Thermo Fisher Scientific. The other authors of this manuscript have no financial disclosures or conflicts of interest to disclose as described by BMC Cancer.

Figures

Fig. 1
Fig. 1
Anti-SARS-CoV-2 RBD antibody titers of 44 patients with multiple myeloma one month after two-dose SARS-CoV-2 mRNA vaccination. Results range from <0.4 to >250 U/mL with detectable antibody defined as an anti-SARS-CoV-2 RBD antibody titer >0.79 U/mL by the manufacturer
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Martínez-López J, Mateos MV, Encinas C, Sureda A, Hernández-Rivas JÁ, de la Guía AL, et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer J. 2020;10(10):1–1. doi: 10.1038/s41408-020-00372-5. - DOI - PMC - PubMed
    1. Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Terpos E, Dimopoulos MA. SARS-CoV-2 Vaccines in Patients With Multiple Myeloma. HemaSphere 2021, 5(3):e547. - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England J Med. 2020;383(25):2439–50. - PMC - PubMed
    1. Connolly CM, Ruddy JA, Boyarsky BJ, Avery RK, Werbel WA, Segev DL, et al. Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021;80(8):1100–1. - PMC - PubMed

MeSH terms